MedPath

Comparison of the efficacy of oral fluconazole and oral Terbinafine in the treatment of moderate to severe seborrheic dermatitis

Phase 2
Conditions
Seborrhoeic dermatitis.
Seborrhoeic dermatitis
Registration Number
IRCT201102205871N1
Lead Sponsor
Gilan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
64
Inclusion Criteria

Patients with moderate to severe seborrheic dermatitis¸ filling the consent form,no previous treatment history at least 2 weeks before entering the study such as steroids, antifungal agents.
Exclusion criteria:Lactation ¸ pregnancy ¸ no pervious diseases such as renal and liver failure, psoriasis, documented human immunodeficiency virus infection and/or sensitivity to fluconazole and terbinafine

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
SDASI (Seborrheic dermatitis area severity index). Timepoint: weeks 4 , 6. Method of measurement: Determine severity of disease by examiner according to SDASI.;Itch. Timepoint: 4 weeks later and 6 weeks later. Method of measurement: subjective.
Secondary Outcome Measures
NameTimeMethod
Side effects. Timepoint: at first,two and four weeks after treatment. Method of measurement: history,physical exam, laboratory tests.
© Copyright 2025. All Rights Reserved by MedPath